Nektar (NKTR) Stock Rises on Positive Dermatitis Drug Data

Key Developments

Nektar Therapeutics (NASDAQ:NKTR) stock increased by 3% after the company announced positive maintenance data from its REZOLVE-AD study. The trial is for rezpegaldesleukin, its novel treatment for patients with moderate-to-severe atopic dermatitis.

Clinical Trial Overview

The global Phase 2b study data showed that patients maintained high response rates across key endpoints at week 52. With monthly dosing, 71% of patients maintained EASI-75 responses, while the quarterly dosing regimen achieved an 83% response rate. The drug's safety profile remained consistent and well-tolerated.

Market and Future Outlook

The company stated that these results validate the drug's novel regulatory T-cell mechanism. This positive data supports advancing the program to a pivotal Phase 3 study, which will evaluate both monthly and quarterly maintenance dosing regimens.

Conclusion

The durable efficacy and consistent safety profile position rezpegaldesleukin for late-stage development. Nektar Therapeutics is now aiming to submit a Biologics License Application (BLA) for the treatment to regulators in 2029.

FAQ

Q: What is rezpegaldesleukin?
A: It is a first-in-class regulatory T-cell biologic developed by Nektar Therapeutics to treat moderate-to-severe atopic dermatitis.

Q: What are the next steps for Nektar's drug?
A: Nektar plans to advance rezpegaldesleukin into a Phase 3 clinical program and intends to file for regulatory approval in 2029.

Source: Investing.com